Publication: 2626

Publication: 2626

A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9).

PubMed

DOI

Google Scholar

Citation:: Lung Cancer vol 68 (2) 234-9

Year:: 2010
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:

Parents:: None
Children:: None

Program:: CCP
Primary Committee:: Symptom Inter
Sec. Committees:

Pharmas:
Grants:: K24 CA131099, UG1 CA189823

Corr. Author:
Authors:: Aminah Jatoi Howard L Ritter Amylou Dueck Phuong L Nguyen Daniel A Nikcevich Ronnie F Luyun Bassam I Mattar Charles L Loprinzi

Networks:

Study: NCCTG-N01C9
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords:: Aged, Aged, 80 and over, Antibodies, Monoclonal, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Fatigue, Female, Genetic Association Studies, Genotype, Humans, Infliximab, Lung Neoplasms, Male, Polymorphism, Genetic, Quality of Life, Taxoids, Tumor Necrosis Factor-alpha, Weight Loss